Letter to the Editor
Leukemia (2008) 22, 1289; doi:10.1038/sj.leu.2405047; published online 13 December 2007
JAK2 Mutations are present in all cases of polycythemia vera
Y L Wang1, K Vandris2, A Jones3, N C P Cross3, P Christos4, F Adriano2 and R T Silver2
- 1Molecular Hematopathology Laboratory, Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY, USA
- 2Division of Hematology–Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA
- 3Wessex Regional Genetics Laboratory, Salisbury District Hospital, University of Southampton, Salisbury, Wiltshire, UK
- 4Division of Biostatistics and Epidemiology, Department of Public Health, Weill Medical College of Cornell University, New York, NY, USA
Correspondence: RT Silver, E-mails: rtsilve@med.cornell.edu; Y L Wang, lyw2001@med.cornell.edu
Top of page
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
RESEARCH
JAK2V617F mutational frequency in polycythemia vera: 100%, >90%, less?
Leukemia Letter
Detection of a new JAK2 D620E mutation in addition to V617F in a patient with polycythemia vera
Leukemia Letter
Leukemia Original Article
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2 V617F
Leukemia Original Article
